PharmaBlock Sciences (Nanjing), Inc.

PharmaBlock Sciences (Nanjing), Inc. has seen notable stock activity, achieving significant weekly and monthly gains. Despite a strong year-to-date performance, the company faces long-term growth challenges, reflected in its five-year decline. Financial metrics indicate a market capitalization of CNY 9,390 million and a P/E ratio of 40.00.

PharmaBlock Sciences (Nanjing), Inc. faced notable stock volatility on July 17, 2026, with a significant decline amid a broader market downturn. The company has experienced mixed performance over various time frames, struggling with flat net sales growth and declining operating profits, while maintaining a fair valuation.

PharmaBlock Sciences (Nanjing), Inc. saw a notable increase on July 10, 2026, contrasting with a decline in the China Shanghai Composite. Despite recent gains, the company has faced challenges, including a negative annual return and decreased profits, while its market capitalization stands at CNY 5,989 million.

PharmaBlock Sciences (Nanjing), Inc. saw a notable increase in its stock performance on June 29, 2026, achieving an intraday high. Despite recent gains, the company's year-to-date performance remains negative, and its long-term outlook shows mixed results, reflecting a challenging market environment.

PharmaBlock Sciences (Nanjing), Inc. saw a notable decline in its stock today, contrasting with the broader market's performance. Over recent weeks and months, the stock has faced significant losses, reflecting ongoing challenges. Despite this, the company retains a market capitalization of CNY 7,711 million and a price-to-earnings ratio of 49.00.